(Q33338535)

25 July 2017

title

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma (English)

1 reference

ORCID Public Data File 2021

25 July 2017

0 references

1 reference

1 reference

1 reference

author name string

P A Philip

1

1 reference

25 July 2017

M M Zalupski

2

1 reference

25 July 2017

V K Vaitkevicius

3

1 reference

25 July 2017

P Arlauskas

4

1 reference

25 July 2017

R Chaplen

5

1 reference

25 July 2017

L K Heilbrun

6

1 reference

25 July 2017

V Adsay

7

1 reference

25 July 2017

D Weaver

8

1 reference

25 July 2017

A F Shields

9

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

92

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

569-577

1 reference

25 July 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

The role of gemcitabine in the treatment of other tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

Phase II study of gemcitabine in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010801%2992%3A3%3C569%3A%3AAID-CNCR1356%3E3.0.CO%3B2-D

10.1002/1097-0142(20010801)92:3<569::AID-CNCR1356>3.0.CO;2-D

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference